These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1007 related articles for article (PubMed ID: 32768971)
1. Natural history of COVID-19 and current knowledge on treatment therapeutic options. Dos Santos WG Biomed Pharmacother; 2020 Sep; 129():110493. PubMed ID: 32768971 [TBL] [Abstract][Full Text] [Related]
2. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Uzunova K; Filipova E; Pavlova V; Vekov T Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial. Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849 [TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
5. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK mBio; 2020 May; 11(3):. PubMed ID: 32444382 [TBL] [Abstract][Full Text] [Related]
6. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817 [TBL] [Abstract][Full Text] [Related]
7. Current pharmacological treatments for SARS-COV-2: A narrative review. Nittari G; Pallotta G; Amenta F; Tayebati SK Eur J Pharmacol; 2020 Sep; 882():173328. PubMed ID: 32603692 [TBL] [Abstract][Full Text] [Related]
8. Macrolide treatment for COVID-19: Will this be the way forward? Ohe M; Shida H; Jodo S; Kusunoki Y; Seki M; Furuya K; Goudarzi H Biosci Trends; 2020 May; 14(2):159-160. PubMed ID: 32249257 [TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Different Therapeutic Interventions on Prevention and Treatment of COVID-19. Gyanwali P; Sharma S; Pant S; Koirala P; Adhikari K; Koirala J; Dhimal M J Nepal Health Res Counc; 2020 Sep; 18(2):151-158. PubMed ID: 32969369 [TBL] [Abstract][Full Text] [Related]
13. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Abd El-Aziz TM; Stockand JD Infect Genet Evol; 2020 Sep; 83():104327. PubMed ID: 32320825 [TBL] [Abstract][Full Text] [Related]
14. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. Fantini J; Chahinian H; Yahi N Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156 [TBL] [Abstract][Full Text] [Related]
15. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406 [TBL] [Abstract][Full Text] [Related]
16. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. Li L; Wang X; Wang R; Hu Y; Jiang S; Lu X Drug Des Devel Ther; 2020; 14():3001-3013. PubMed ID: 32801640 [TBL] [Abstract][Full Text] [Related]
17. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial. Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363 [TBL] [Abstract][Full Text] [Related]
18. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial. Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611 [TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Mehta N; Mazer-Amirshahi M; Alkindi N; Pourmand A Am J Emerg Med; 2020 Jul; 38(7):1488-1493. PubMed ID: 32336586 [TBL] [Abstract][Full Text] [Related]
20. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? Quiros Roldan E; Biasiotto G; Magro P; Zanella I Pharmacol Res; 2020 Aug; 158():104904. PubMed ID: 32430286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]